Mr Gill is a highly accomplished commercial leader with over 20 years' experience in driving growth in the Healthcare and FMCG industries. He has played a major role in developing many internationally recognised brands, including Voltaren, Otrivin, Panadol, Sensodyne and Parodontax.
He also has long established relationships with the largest pharmacies in the US such as the Walgreens Boots Alliance and AS Watsons, amongst others. Mr. Gill has held several senior commercial leadership positions in both Novartis Consumer Health and GSK Consumer
His extensive global experience and knowledge with regards to placing health care & OTC products into the hands of consumers should prove an invaluable addition to HBC´s product development, strategy and sales efforts.
HBC can now accelerate its journey to commercialise and shift over 5000t of output in commoditised animal feed markets, towards much higher value human and pet supplement markets through Mr Gill's access to international pharmacy and drug store chains and then direct to the consumer via white label and own branded products.
"I am excited to be joining HBC at this critical time as they expand their commercial operations and accelerate their growth. The global consumer trends of increased self-care and demand for natural products presents a huge opportunity for HBC to meet these needs through their state-of-the-art production facilities and innovative product portfolio.", Andy Gill says.
Mr Gill´s role will help and complement HBC´s engagement with specialised distributors B2B with global reach and its direct sales efforts B2C via online platforms and the Hofseth Group´s established retail network.
"Hiring Andy Gill is an extremely significant milestone for HBC and we are delighted to have him onboard. Hiring a senior leader from one of the world's leading Consumer Health companies after nearly 25 years of combined experience at Novartis and GSK speaks volumes about the opportunity and current outlook at HBC. All of our by-products (oil, proteins and collagen) have a very differentiated evidence-based health benefits and Andy's addition is an enormous step forward for us to begin the process of selling more both B2B and B2C", says CEO Roger Hofseth of Hofseth BioCare ASA.